abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English


9 Jan 2010

Glaxo Smith Kline

Glaxo Smith Kline response re HPV vaccine testing in India

Cervarix® is designed to offer women protection against cervical cancer. Cervarix® provides protection against the most common cancer-causing virus types — HPV 16 and 186, 7. These virus types are responsible for over 70 percent of all cervical cancer cases worldwide8...To date GSK’s vaccine against HPV, Cervarix® has been approved in over 100 countries around the world, including the 27 member states of the European Union ...Since its launch in 2007, Cervarix has been administered to millions of women. The vaccine has been selected for immunisation programmes in five countries, including national programmes in the Netherlands and the UK and regional programmes across Italy, Poland and Spain...Results from the largest global efficacy trial of a cervical cancer vaccine, involving 18,644 women and published in The Lancet showed that Cervarix® offers Protection’ against the five most common cancer-causing virus types.